PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Researchers suggest form of Alzheimer’s is transmissible via bone marrow transplants

The progressive neurodegenerative disease is estimated to affect 24 million people globally.

Researchers from the University of British Columbia in Canada have revealed that a form of Alzheimer’s disease (AD) can be transmissible via bone marrow transplants.

Published in Stem Cell Reports, researchers believe that amyloid build-up in the brain in AD can be caused by the presence of amyloid outside of the brain.

Currently the most frequent cause of dementia, affecting an estimated 24 million people globally, AD is a brain disorder that progressively deteriorates memory and thinking skills and, eventually, the ability to carry out simple tasks.

Researchers took bone marrow cells from mice that carried a defective version of a gene linked to AD known as the amyloid precursor protein (APP) gene and transplanted them into healthy mice that lacked this genetic fault.

The APP gene plays a pivotal role in producing the APP protein found in tissues and organs, including the brain.

Following transplantation, both groups of mice were found to have developed AD, which researchers identified through symptoms of cognitive decline as well as increased levels of amyloid, a key hallmark of AD, in the brain.

In comparison, researchers found that both groups of mice developed symptoms earlier than the donor mice, which already carried the faulty APP gene.

As researchers used stem cells that had the potential to develop into blood and immune cells but not into nerve cells in the study, they suggest that amyloid build-up in the brain in AD could be triggered by the presence of amyloid outside of the brain.

Dr Chaahat Singh, first author of the study, University of British Columbia, said: “The fact that we could see significant behavioural differences and cognitive decline in the APP-knockouts at six months was surprising but also intriguing because it just showed the appearance of the disease that was being accelerated after being transferred.”

Researchers plan to test whether other types of transplants may have similar results.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026